Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267863 · ClinicalTrials.gov registry record · Phase 1
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
A Phase 1 study, sponsored by Aptose Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02267863: Clinical Trial Phase 1 study, sponsored by Aptose Biosciences.
NCT02267863 is a Phase 1 study that was terminated before completion, run by Aptose Biosciences. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02267863, a Phase 1 study, was terminated before completion, sponsored by Aptose Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being.
Primary Outcome
To determine the safety and tolerability of APTO-253 by assessing treatment-related adverse events as assessed by CTCAE v4.0.
Interventions
- DRUG APTO-253
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-10 |
| Est. Completion | 2021-09 |
| Phase | Phase 1 |
Why NCT02267863 stopped before completion
NCT02267863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which APTO-253 is the first listed.
NCT02267863 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02267863 about?
NCT02267863 is a clinical study titled "A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS". This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be adminis...
What is the current status of trial NCT02267863?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2014-10. Estimated completion is 2021-09.
What interventions are being tested in trial NCT02267863?
The interventions under investigation include: APTO-253 (DRUG).
Who is sponsoring clinical trial NCT02267863?
This trial is sponsored by Aptose Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02267863's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia